Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

BÜHLMANN fCAL® ELISA Citation

Foster, A. et al. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol. PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266.

Highlight from this Publication

…”Notably, in keeping with adult IBD practice, our study shows that children should also have FC levels checked every 3 mo to ensure adequate monitoring.“…

Read Citation

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.

Health Canada License: 80726

This citation describes applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.)